NV

Novo Integrated Sciences IncNASDAQ NVOS Stock Report

Last reporting period 31 May, 2024

Updated 21 Nov, 2024

Last price

Market cap $B

0.006

Micro

Exchange

XNAS - Nasdaq

NVOS Stock Analysis

NV

Uncovered

Novo Integrated Sciences Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-52/100

Low score

Market cap $B

0.006

Dividend yield

Shares outstanding

135.65 B

Novo Integrated Sciences, Inc. engages in the provision of medical services. The company is headquartered in Bellevue, Washington and currently employs 113 full-time employees. The company went IPO on 2005-07-12. The firm owns Canadian and United States subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutic, diagnostic solutions, personalized product offerings, and rehabilitative science. The firm operates through two segments: Healthcare Services and Product Sales. Its specialized multidisciplinary primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy (including pre- and post-partum), acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, dietician and others. The firm's products include ProDip and Terragenx.

View Section: Eyestock Rating